Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Businessweek Archives

Is Warner Lambert On The Block?

Inside Wall Street


Takeover frenzy in the pharmaceutical industry has picked up, fueled by American Cyanamid's acceptance of a sweetened $101-a-share from American Home Products. The question titillating the Street: "Who's next?"

High on the takeover-target list is Warner-Lambert, a maker of prescription and over-the-counter drugs. Whispers are that management, feeling the buyout pressure as the stock climbed--from 60 in March to 791/2 lately--is considering selling its drug operations, which analysts figure would bring $45 to $50 a share. Warner-Lambert will have no difficulty finding a buyer, says one New York investment manager. Sales hit $5.7 billion last year.

As an alternative move, according to this pro, Warner-Lambert may spin off parts of its two other units: consumer health care and the gum-and-mints operation. Health-care products include Listerine, Bromo-Seltzer, and Schick and Wilkinson Sword razors. Gum and mints include Dentyne, Trident, Clorets, and Certs. The units are estimated to be worth $60 a share.

Warner-Lambert has a breakup value of about $100 a share, figures Mike Metz of Oppenheimer. He says he wouldn't be surprised if Warner-Lambert broke up the company to stave off a buyout offer. But analyst Neil Sweig of Ladenburg Thalmann predicts Warner-Lambert will be acquired by a larger company this year. European giants Ciba-Geigy, Glaxo, and Hoffmann-La Roche are possible buyers. Warner-Lambert declined to comment.GENE G. MARCIAL

blog comments powered by Disqus